✦ LIBER ✦

6589 Biweekly treatment with Docetaxel-Gemcitabine and Erlotinib in patients with metastatic and/or unresectable pancreatic cancer offers a survival benefit

✍ Scribed by Samelis, G.; Tsiakou, A.; Karamanides, M.; Pelechrini, M.; Zaganides, A.; Ekmektzoglou, K.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improvement in survival and clinical ben

✍ R Dobrila-Dintinjana; D Kovać; A Depolo; M Uravić; M Dintinjana 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 35 KB

Cetuximab, gemcitabine, and oxaliplatin

✍ Birgit Gruenberger; Johannes Schueller; Ute Heubrandtner; Fritz Wrba; Dietmar Ta 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 180 KB

First line treatment with docetaxel (D)

✍ N. Androulakis; G. Stathopoulos; N. Tsavaris; G. Aravandinos; E. Samantas; P. Pa 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Frontline treatment with gemcitabine, ox

✍ Katopodis, O.; Souglakos, J.; Stathopoulos, E.; Christopoulou, A.; Kontopodis, E 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 440 KB

A phase II trial of gemcitabine and cape

✍ Syma Iqbal; Cathryn Rankin; Heinz-Josef Lenz; Philip J. Gold; Syed A. Ahmad; Ant 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 243 KB

Comorbidity, age and overall survival in

✍ M.M. Vickers; E.D. Powell; T.R. Asmis; D.J. Jonker; J.F. Hilton; C.J. O’Callagha 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 305 KB